针刺联合推拿功法治疗“方舱综合征”的随机对照研究

注册号:

Registration number:

ITMCTR2200005987

最近更新日期:

Date of Last Refreshed on:

2022-05-10

注册时间:

Date of Registration:

2022-05-10

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺联合推拿功法治疗“方舱综合征”的随机对照研究

Public title:

Acupuncture combined with Tuina for treatment of

注册题目简写:

针刺联合推拿功法治疗“方舱综合征”

English Acronym:

研究课题的正式科学名称:

针刺联合推拿功法治疗奥密克戎感染患者“方舱综合征”的随机对照研究

Scientific title:

Acupuncture combined with Tuina for treatment of

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200059746 ; ChiMCTR2200005987

申请注册联系人:

魏绪强

研究负责人:

赵庆

Applicant:

Xuqiang Wei

Study leader:

Qing Zhao

申请注册联系人电话:

Applicant telephone:

+86 18916026080

研究负责人电话:

Study leader's telephone:

+86 18930568563

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wxqzdyx123@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhaoqing_1967@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区甘河路110号

研究负责人通讯地址:

上海市虹口区甘河路110号

Applicant address:

No.110, Ganhe Rd.,Hongkou District, Shanghai

Study leader's address:

No.110, Ganhe Rd.,Hongkou District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属岳阳中西医结合医院

Applicant's institution:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2022-037

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海中医药大学附属岳阳中西医结合医院伦理委员会

Name of the ethic committee:

Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/3/4 0:00:00

伦理委员会联系人:

殷从全

Contact Name of the ethic committee:

Congquan Yin

伦理委员会联系地址:

上海市虹口区甘河路110号

Contact Address of the ethic committee:

No.110, Ganhe Rd.,Hongkou District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属岳阳中西医结合医院

Primary sponsor:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市虹口区甘河路110号

Primary sponsor's address:

No.110, Ganhe Rd.,Hongkou District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属岳阳中西医结合医院

具体地址:

上海市虹口区甘河路110号

Institution
hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Address:

No.110, Ganhe Rd.,Hongkou District, Shanghai

经费或物资来源:

上海中医药大学

Source(s) of funding:

Shanghai University of Traditional Chinese Medicine

研究疾病:

方舱综合征

研究疾病代码:

Target disease:

shelter syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

评价针刺联合易筋经治疗奥密克戎感染患者“方舱综合征”的有效性及安全性。

Objectives of Study:

To evaluate the efficacy and safety of acupuncture combined with Yijinjing in the treatment of "shelter syndrome" in patients with Omicron infection.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合“方舱综合征”诊断; (2)18岁≤年龄≤80岁,性别不限; (3)自愿参加病例注册登记研究,并签署知情同意书。

Inclusion criteria

(1) Consistent with the diagnosis of "shelter syndrome"; (2)18≤age≤80 years old, no gender limitation; (3) Voluntarily participate in the case registration study and sign the informed consent.

排除标准:

(1)研究者认为可能影响疗效评估的严重全身性疾病(即恶性肿瘤、自身免疫性疾病、肝脏或肾脏疾病)或手术(脾切除术、器官移植)及凝血功能障碍者; (2)严重的精神疾病或者认知功能障碍患者; (3)参加本研究前两周内因失眠、焦虑、抑郁接受过任何治疗; (4)急性外伤、骨折等无法进行功法训练者; (5)妊娠或哺乳期的妇女; (6)排除2周内参加过其他临床研究或正在参加其他临床研究者

Exclusion criteria:

(1) patients with severe systemic diseases (i.e., malignant tumor, autoimmune disease, liver or kidney disease) or surgery (splenectomy, organ transplantation) and coagulation disorders that the investigator considers may affect the efficacy evaluation; (2) patients with severe mental illness or cognitive dysfunction; (3) Received any treatment for insomnia, anxiety, and depression within two weeks before participating in this study; (4) acute trauma, fracture, etc., unable to perform skills training; (5) pregnant or breast-feeding women; (6) Participants in other clinical studies or participating in other clinical investigators within 2 weeks were excluded

研究实施时间:

Study execute time:

From 2022-05-07

To      2022-06-30

征募观察对象时间:

Recruiting time:

From 2022-05-07

To      2022-06-30

干预措施:

Interventions:

组别:

A

样本量:

60

Group:

A

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

Usual care

Intervention code:

组别:

B

样本量:

60

Group:

B

Sample size:

干预措施:

针刺联合易筋经+常规护理

干预措施代码:

Intervention:

acupuncture combination Yijinjing plus Usual care

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属岳阳中西医结合医院

单位级别:

三级甲等

Institution/hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary Grade A

测量指标:

Outcomes:

指标中文名:

GAD-7焦虑评分

指标类型:

次要指标

Outcome:

GAD-7

Type:

Secondary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

Questionnaire scale

指标中文名:

ISI评分

指标类型:

主要指标

Outcome:

ISI index

Type:

Primary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

Questionnaire scale

指标中文名:

PHQ-9焦虑量表

指标类型:

次要指标

Outcome:

Type:

Secondary indicator

测量时间点:

PHQ-9

测量方法:

量表

Measure time point of outcome:

Measure method:

Questionnaire scale

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计师通过SPSS25软件生成随机代码

Randomization Procedure (please state who generates the random number sequence and by what method):

Statisticians generate random codes using SPSS25 software

盲法:

对统计师施加盲法

Blinding:

Blind statisticians

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向负责人获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

available from the study leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统